UCL (University College London) has an ongoing drug discovery program for the treatment of vascular collapse during sepsis (collapsing of blood vessels due to systemic infection by a pathogen). Galapagos’s BioFocus DPI service division will provide medicinal chemistry services to progress UCL’s lead series through to pre-clinical testing.
In addition UCL will also have the opportunity to utilize BioFocus DPI ADME screening services and will receive access to a selection of compounds in BioFocus DPI’s SoftFocus collection to facilitate the identification of new chemical starting points for this drug discovery program.
Onno van de Stolpe, CEO of Galapagos, said: “BioFocus DPI’s medicinal chemistry and ADME expertise, such as the newly launched ADME/PK Laboratory, give us a strong edge in winning highly competitive deals.”